Handelsavisen
prelaunch
Companies Healthcare ABDX.L
AB
ABDX.L London Stock Exchange Medical Equipment, Supplies & Distribution

Abingdon Health PLC

$12,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-41,6 %
ROE
-64,4 %
Net margin
-40,5 %
Debt / equity
0,19
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

ABDX.L operates in the healthcare services and equipment industry, primarily engaged in the distribution of medical equipment and supplies.

Business. ABDX.L is a healthcare company operating within the Medical Equipment, Supplies & Distribution industry. The firm generates revenue through the sale of medical products and is headquartered in the United Kingdom. It is primarily listed on the London Stock Exchange under the ticker ABDX.L. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target40,00

Analyst recommendations

2 analysts · consensus Buy
Buy2
Hold0
Sell0
12-month price target
40,00
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
2 analysts · indicative
Ownership
not yet wired
Profitability
-64,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ABDX.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ABDX.L. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    ABDX.L is a healthcare company operating within the Medical Equipment, Supplies & Distribution industry. The firm generates revenue through the sale of medical products and is headquartered in the United Kingdom. It is primarily listed on the London Stock Exchange under the ticker ABDX.L. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    ABDX.L's capital structure is characterized by a current ratio of 1.76, indicating a moderate level of liquidity, and a debt-to-equity ratio of 0.19, suggesting a relatively low reliance on debt financing. The company holds GBP 1.92 million in cash and equivalents, which is a significant portion of its total assets of GBP 9.31 million. However, the company reported negative operating and free cash flows of GBP -3.18 million and GBP -3.15 million, respectively, indicating a cash outflow from operations.

    Profitability metrics for ABDX.L are concerning, with a return on equity of -0.6443 and a return on assets of -0.3667, both significantly below the industry norms. The company reported a net loss of GBP -3.42 million, and an operating loss of GBP -3.51 million, which is a clear indicator of financial distress. These figures suggest that the company is not generating sufficient returns to cover its costs and is underperforming relative to its industry peers.

    The company's revenue is concentrated in the healthcare services and equipment sector, with no disclosed geographic diversification. This concentration may expose the company to specific market risks, particularly in the UK where it is listed. The lack of geographic diversification could limit its ability to mitigate risks associated with regional economic downturns or regulatory changes.

    Looking at the growth trajectory, ABDX.L is currently experiencing a decline in profitability, as evidenced by its negative operating and net income. The company's future growth is uncertain, and there are no disclosed plans for expansion or new product development. The lack of positive growth indicators, combined with the current financial losses, suggests that the company may need to implement significant cost-cutting measures or find new revenue streams to improve its financial position.

    The risk assessment for ABDX.L indicates a low level of liquidity and dilution risk. However, the company's negative cash flows and operating losses pose a significant financial risk. The absence of immediate filing-based liquidity or dilution flags is a positive sign, but the company's financial performance suggests that it may need to seek additional financing in the near future. The dilution potential is currently low, but this could change if the company needs to raise capital through equity issuance.

    Recent events and filings do not indicate any major changes in the company's operations or financial strategy. The company's financial performance has been declining, and there are no disclosed plans to address this issue. The lack of positive developments in the company's operations or financial strategy is a concern for investors and stakeholders.

    Key takeaways
    • ABDX.L is experiencing significant financial losses, with a net loss of GBP -3.42 million and an operating loss of GBP -3.51 million.
    • The company's liquidity is moderate, with a current ratio of 1.76 and GBP 1.92 million in cash and equivalents.
    • Profitability metrics are poor, with a return on equity of -0.6443 and a return on assets of -0.3667.
    • The company's revenue is concentrated in the healthcare services and equipment sector, with no geographic diversification.
    • The company's growth trajectory is uncertain, and there are no disclosed plans for expansion or new product development.
    • The risk assessment indicates a low level of liquidity and dilution risk, but the company's financial performance suggests a need for additional financing.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $12,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $5.3M
    Net cash
    $890.0k
    Current ratio
    1.8
    Debt / equity
    0.2
    ROA
    -36.7%
    ROE
    -64.4%
    Cash conversion
    93.0%
    CapEx / revenue
    -4.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,00
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    2
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-08 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,00
    Revenueno estimateno estimate15,5M GBP
    Operating incomeno estimateno estimate-1,1M GBP
    Full-year consensus mean (period as reported by source) · consensus in GBP. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy1
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$40,00 · Median $40,00
    Low $19,00High $61,00
    Operating income · consensus-1,1M GBP
    EPS surprise
    −814,1 %
    reported vs consensus · miss
    Revenue surprise
    −45,6 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$19,00
    Mean$40,00
    Median$40,00
    High$61,00
    Spot$12,00
    +233.3 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-41,6 %Bottom quartile
    Net Margin-40,5 %Bottom quartile
    ROE-64,4 %Bottom quartile
    Capex / Rev-4,1 %Above median
    D/E0,19Below median
    Cash Conv0,93Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • ABDX.L Market data — financials · 2026-05-27
    • Abingdon Health PLC Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ABDX.LCanonical
    London Stock Exchange · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage